Davita Inc vs Ishares Msci Brazil ETF — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Ishares Msci Brazil ETF trades at $34. Which is the better fit depends on your goals.
| DVA | EWZ | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $41.75 |
52-Week Low | $103.87 | $27.36 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
EWZ trades at $35.34, down 1.31% today, with a bearish technical signal from moving averages. The ETF tracks Brazilian equities, facing headwinds from US tariffs and currency volatility. Recent institutional buying includes Empowered Funds' $3.06 million position (Defense World, Aug 5, 2026), while technical support sits at $34-$35.
Outlook hinges on Brazil's economic policies and commodity prices. Opportunities exist if rate cuts continue, but risks include political uncertainty and competitive pressure from lower-fee alternatives like FLBR. The dividend yield of approximately 3.78% provides income, but consistency is challenged by reliance on commodity-driven holdings.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →